Claude Cances

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

TTC19-related mitochondrial disease: A characteristic neuroimaging signature?

TTC19-related mitochondrial disease: A characteristic neuroimaging signature?

Journal: Molecular genetics and metabolism

Published: June 02, 2026

Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies: Phenotype, Genotype, and Outcome.

Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies: Phenotype, Genotype, and Outcome.

Journal: Neurology

Published: May 26, 2026

Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Journal: Nature medicine

Published: January 28, 2026

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.

Journal: Expert review of neurotherapeutics

Published: November 13, 2025

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Journal: JAMA network open

Published: October 08, 2025

Phenotype-specific muscle proteomic profiling in titinopathies.

Phenotype-specific muscle proteomic profiling in titinopathies.

Journal: Acta neuropathologica communications

Published: September 12, 2025

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Journal: Nature medicine

Published: July 23, 2025

REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France.

REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France.

Journal: Journal of neuromuscular diseases

Published: July 08, 2025

Prevalence of pediatric neuromuscular disorders in the Southwest region of France.

Prevalence of pediatric neuromuscular disorders in the Southwest region of France.

Journal: Neuromuscular disorders : NMD

Published: May 27, 2025

Innovative treatments of pediatric spinal muscular atrophy: The decision-making process in France.

Innovative treatments of pediatric spinal muscular atrophy: The decision-making process in France.

Journal: European journal of medical genetics

Published: May 16, 2025

Diagnostic Impasse and Wandering in Patients With Rare Neuromuscular Diseases: Insights Into Patient Characteristics From the French National Network for Rare Neuromuscular Diseases (FILNEMUS) and the French National Rare Disease Database (BNDMR).

Diagnostic Impasse and Wandering in Patients With Rare Neuromuscular Diseases: Insights Into Patient Characteristics From the French National Network for Rare Neuromuscular Diseases (FILNEMUS) and the French National Rare Disease Database (BNDMR).

Journal: European journal of neurology

Published: April 03, 2025

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

Journal: The Lancet. Neurology

Published: March 25, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026